Media stories about PhaseRx (NASDAQ:PZRX) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PhaseRx earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 48.3633594225732 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Separately, Laidlaw lowered shares of PhaseRx from a “buy” rating to a “neutral” rating in a report on Friday, October 13th.
Shares of PhaseRx (NASDAQ PZRX) opened at $0.65 on Tuesday. PhaseRx has a twelve month low of $0.54 and a twelve month high of $3.30. The company has a debt-to-equity ratio of -12.03, a current ratio of 2.14 and a quick ratio of 2.14.
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
Receive News & Ratings for PhaseRx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.